1. Campbell R. Myocardial infarction: International guidelines. M.: 1997; 87 p. (InRuss.) Kэмпбелл Р. Международное руководство по инфаркту миокарда. М.: 1997; 87 c.
2. Сhambless L, Keil U, Dobson A, et al. Population versus clinical view of case fatality from acute coronary heart disease: results from WHO MONICA 1985-1990. Circulation 1997; 96: 3849-59.
3. Kesov PG, Shalaev SV. Risk factors, clinical manifestations, and especially the treatment of acute coronary syndrome from the standpoint of the gender perspective. Meducal science and education of Ural 2015; 16 (2): 164-8. (In Russ.) Кесов П.Г., Шалаев С.В. Факторы риска, клинические проявления и особенности терапии острого коронарного синдрома с позиции гендерных аспектов. Медицинская наука и образование Урала 2015; 16 (2): 164-8.
4. Thygesen K, Alpert JS, Jaffe AS, et al. Third Universal Definition of Myocardial Infarction. Circulation 2012; 126 (16): 2020-35.
5. Thygesen K, Mair J, Giannitsis E, et al. How to Use High — Sensititity Cardiac Troponins in Acute Cardiac Care. Eur Heart J 2012; 33 (18): 2252-7.
6. Jobs A, Thiele H. ESC guidelines 2015: NonSTelevation acute coronary Syndrome. Herz 2015; 40 (8): 1027-33.
7. Khan SQ. C-Terminal Provasopressin (Copepnin) as a Novel and Prognostic Marker in Acute Myocardial Infarction. LAMP Study. Circulation 2007; 115: 2103-10.
8. Preibisz JJ, Sealey JE, Laragh JH, et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983; 5: 1129-38.
9. Kokorin VA, Luyson VA, Shaiduyk OY. Increased activity neurohumoral systems of myocardial infarction patients: prognostic importance. Scientific records sevics of Medicine. Pharmacy 2011; 10 (105): 37-43. (In Russ.) Кокорин В.А., Люсов В.А., Шайдюк О.Ю. Прогностическая значимость повышения активности нейрогуморальных систем у больных инфарктом миокарда. Научные ведомости. Серия Медицина. Фармация. 2011; 10 (105): 37-43.
10. Muller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarkers, in lower respiratory tract infections. Eur J of Clinical Invest 2007; 37 (2): 145-52.
11. Morgenthaler N, Muller B, Struck J, et al. Copepnin a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007; 28 (2): 219-26.
12. Katan M, Fluri F, Morgenthaler N, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann of Neurology 2009; 66 (6): 799-808.
13. Sang G, Du J-M, Chen YY, et al. Plasma copeptin levels are associated with prognosis of severe acute pancreatitis. Peptides 2014; 51: 4-8.
14. Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009; 54 (1): 60-8.
15. Gu YL, Voors AA, Zijlstra F, et al. Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin Res Cardiol 2011; 100 (12): 1069-76.
16. Ananth V, Beig JR, Tramboo N, et al. Does plasma copeptin level at admission predict final infarct size in ST — elevation myocardial infarction. International J of Cardiology 2016; 219: 326-30.
17. Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010; 55 (19): 2096-106.
18. Afzali D, Erren M, Pavenstadt H-J, et al. Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes. Clin Research in Cardiology 2013; 102: 755-63.
19. Folli Ch, Consonni D, Spessot M, et al. Diagnostic rolle of copeptin in patients presenting with chest pain in the emergency room. Eur J of Internal Medicine 2013; 24 (2): 189-93.
20. El Sayed ZH, Mahmoud HA, El Shall LY, et al. Impact of copeptin on diagnosis of acute coronary syndrome. Egyptian J of Medical Human Genetics 2014; 15 (3): 241-7.
21. Liorens P, Sanchez M, Herrero P, et al. The utility of copeptin in the emergency department for non — ST — elevation myocardial infarction rapid rule out: COPED-MIRRO study. Eur J Emerg Med 2014; 21 (3): 220-9.
22. Hillinger P, Twerenbold R, Jaeger C, et al. Optimizing early rule-out strategies for acute myocardial infarction: utility of 1-hour copeptin. Clinical Chemistry 2015; 61 (12): 1466-74.
23. Mockel M, Searle J, Hamm Ch, et al. Earle discharge using single cadiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 2014; 36 (6): 369-76.
24. Khan SQ, Dhillon OS, O`Brien RJ, et al. C-Terminal Provasopressin (Copeptin a Novel and Prognostic Marker in Acute Myocardial Infarction. Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Circulation 2007; 115: 2103-10.
25. Narayan H, Dhillon OS, Quinn PA, et al. C-terminal provasopressin (copeptin) as a prognostic marker after acute nonST — elevation myocardial infarction: leicester acute myocardial infarction peptide II (LAMP II) study. Clinical Science 2011; 121 (2): 79-89.
26. Potocki M, Reichlin T, Thalmann S, et al. Diagnostic and prognostic impact of copeptin and high-sensitivity cardiac troponin T in patients with pre-existing coronary artery disease and suspected acute myocardial infarction. Heart 2012; 98 (7): 558-65.
27. O`Malley RG, Bonaca MP, Scirica BM, et al. Prognostic performance of multiple biomarkers in patients with non — ST — segment elevation acute coronary syndrome: analysis from the MERLIN — TIMI 36 trial. J of the American College of Cardiology 2014: 63 (16): 1644-53.
28. Searle J, Slagman A, Stockburger M, et al. Use of copeptin in emergency patients with cardiac chief complaints. Eur Heart J 2015; 4 (5) 393-402.
29. Morawiec B, Kawecki D, Lam Ho, et al. COPeptin for diagnosis and prediction in acute coronary syndrome study: desing and objectives. Postery Kardiol Interwencyjnej 2016; 12 (4): 360-3.
30. Vargas KG, Kassem M, Mueller Ch, et al. Copeptin for the early rule-out of non — ST — elevation myocardial infarction. International J of Cardiology 2016; 223: 797-804.
